Multiple sclerosis medications are commonly called Disease Modifying Therapies (DMTs), mostly working to change the course and progression of the disease rather than cure it. The first of these was introduced in the early 1990s, and the list of approved medications has been growing ever since.
Individualizing treatment according to a patient’s risk profile starting with high-efficacy treatments helps prevent irreversible brain and spinal cord damage, thus leading to better outcomes. The neurology team at the Rocky Mountain MS Center generally categorize today’s many DMTs as follows:
Note: All of the above DMTs are approved for use in patients with relapsing forms of MS; Only ocrelizumab is approved for use in Primary Progressive MS patients.
